科研日报 2026-10-12

Page content

📅 Daily Report - 2026-10-12

今日筛选出 1 条内容,来自 1 个来源

Powered by 科研普拉斯 & Claude

🤖 今日AI智能总结

🧪 博客更新

今日焦点: 免疫疗法在II/III期结直肠癌患者中展现出持久的术前辅助疗效,部分患者肿瘤完全消融并长期维持。

主要方向:

  • 探索免疫疗法作为早期结直肠癌(II/III期)的术前辅助治疗方案。
  • 评估该疗法对特定基因突变患者的长期疗效和复发预防能力。

技术亮点:

  • NEOPRISM-CRC试验首次展示了短期免疫疗法对部分结直肠癌患者的“熔化”效应及持久的无病生存。

📚 分类浏览

🧪 博客更新 (1条)

详细内容(全部1条)

1. 免疫疗法后,肠癌“消失”了,并且没有复发。

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:cancer、regex:immuno(logy|therapy|suppression)
  • 📝 描述:A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of bowel cancer received pembrolizumab for up to nine weeks before surgery instead of the usual post-surgery chemotherapy. After nearly three years of follow-up, none of the patients had experienced a cancer recurrence, including those who still had small traces of disease after treatment.
  • 🔗 查看原文

📊 关键词统计

关键词出现次数
cancer1
regex:immuno(logytherapy

📅 报告生成时间:2026-10-12 00:38
🤖 由 GitHub Actions 自动生成